These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18220932)

  • 1. Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage.
    Kukar T; Golde TE
    Curr Top Med Chem; 2008; 8(1):47-53. PubMed ID: 18220932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations.
    Czirr E; Leuchtenberger S; Dorner-Ciossek C; Schneider A; Jucker M; Koo EH; Pietrzik CU; Baumann K; Weggen S
    J Biol Chem; 2007 Aug; 282(34):24504-13. PubMed ID: 17573346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of gamma-secretase inhibitors and modulators.
    Imbimbo BP
    Curr Top Med Chem; 2008; 8(1):54-61. PubMed ID: 18220933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo.
    Eriksen JL; Sagi SA; Smith TE; Weggen S; Das P; McLendon DC; Ozols VV; Jessing KW; Zavitz KH; Koo EH; Golde TE
    J Clin Invest; 2003 Aug; 112(3):440-9. PubMed ID: 12897211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gamma-secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective.
    Peretto I; La Porta E
    Curr Top Med Chem; 2008; 8(1):38-46. PubMed ID: 18220931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond.
    Leuchtenberger S; Beher D; Weggen S
    Curr Pharm Des; 2006; 12(33):4337-55. PubMed ID: 17105431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds.
    Czirr E; Weggen S
    Neurodegener Dis; 2006; 3(4-5):298-304. PubMed ID: 17047371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition and modulation of gamma-secretase for Alzheimer's disease.
    Wolfe MS
    Neurotherapeutics; 2008 Jul; 5(3):391-8. PubMed ID: 18625450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. gamma-Secretase as a therapeutic target in Alzheimer's disease.
    Guardia-Laguarta C; Pera M; Lleó A
    Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes.
    Imbimbo BP; Giardina GA
    Curr Top Med Chem; 2011; 11(12):1555-70. PubMed ID: 21510832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.
    Weggen S; Eriksen JL; Das P; Sagi SA; Wang R; Pietrzik CU; Findlay KA; Smith TE; Murphy MP; Bulter T; Kang DE; Marquez-Sterling N; Golde TE; Koo EH
    Nature; 2001 Nov; 414(6860):212-6. PubMed ID: 11700559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain.
    Weggen S; Eriksen JL; Sagi SA; Pietrzik CU; Golde TE; Koo EH
    J Biol Chem; 2003 Aug; 278(33):30748-54. PubMed ID: 12777371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of γ-secretase activity in endogenous amyloid-β generation.
    Koch P; Tamboli IY; Mertens J; Wunderlich P; Ladewig J; Stüber K; Esselmann H; Wiltfang J; Brüstle O; Walter J
    Am J Pathol; 2012 Jun; 180(6):2404-16. PubMed ID: 22510327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of notch-sparing gamma-secretase inhibitors.
    Augelli-Szafran CE; Wei HX; Lu D; Zhang J; Gu Y; Yang T; Osenkowski P; Ye W; Wolfe MS
    Curr Alzheimer Res; 2010 May; 7(3):207-9. PubMed ID: 20088802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease.
    Imbimbo BP
    Expert Opin Investig Drugs; 2004 Nov; 13(11):1469-81. PubMed ID: 15500394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease.
    Read J; Suphioglu C
    Cell Physiol Biochem; 2019; 53(2):413-428. PubMed ID: 31415717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.
    Beher D; Clarke EE; Wrigley JD; Martin AC; Nadin A; Churcher I; Shearman MS
    J Biol Chem; 2004 Oct; 279(42):43419-26. PubMed ID: 15304503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-modifying therapies in Alzheimer's disease: how far have we come?
    Hüll M; Berger M; Heneka M
    Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.